Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis Article Swipe
Shohei Yamamoto
,
Kouki Matsuda
,
Kenji Maeda
,
Kumi Horii
,
Kaori Okudera
,
Yusuke Oshiro
,
Natsumi Inamura
,
Takashi Nemoto
,
Junko S. Takeuchi
,
Yunfei Li
,
Maki Konishi
,
K. Tsuchiya
,
Hiroyuki Gatanaga
,
Shinichi Oka
,
Tetsuya Mizoue
,
Haruhito Sugiyama
,
Nobuyoshi Aoyanagi
,
Hiroaki Mitsuya
,
Wataru Sugiura
,
Norio Ohmagari
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/infdis/jiad317
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/infdis/jiad317
Background Data are limited on the role of preinfection humoral immunity protection against Omicron BA.5 infection and long coronavirus disease (COVID) development. Methods We conducted nested case-control analysis among tertiary hospital staff in Tokyo who donated blood samples in June 2022 (1 month before Omicron BA.5 wave), approximately 6 months after receiving a third dose of COVID-19 mRNA vaccine. We measured live virus-neutralizing antibody titers against wild type and Omicron BA.5, and anti–receptor-binding domain (RBD) antibody titers at preinfection, and compared them between cases and propensity-matched controls. Among the breakthrough cases, we examined association between preinfection antibody titers and incidence of long COVID. Results Preinfection anti-RBD and neutralizing antibody titers were lower in cases than controls. Neutralizing titers against wild type and Omicron BA.5 were 64% (95% confidence interval [CI], 42%–77%) and 72% (95% CI, 53%–83%) lower, respectively, in cases than controls. Individuals with previous Omicron BA.1/BA.2 infections were more frequent among controls than cases (10.3% vs 0.8%), and their Omicron BA.5 neutralizing titers were 12.8-fold higher than infection-naive individuals. Among cases, preinfection antibody titers were not associated with incidence of long COVID. Conclusions Preinfection immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may play a role in protecting against the Omicron BA.5 infection but not preventing long COVID.
Related Topics
Concepts
Neutralizing antibody
Titer
Immunogenicity
Virology
Antibody
Antibody titer
Coronavirus disease 2019 (COVID-19)
Medicine
Biology
Immunology
Internal medicine
Disease
Infectious disease (medical specialty)
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/infdis/jiad317
- https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdf
- OA Status
- bronze
- Cited By
- 10
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4387087710
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4387087710Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/infdis/jiad317Digital Object Identifier
- Title
-
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched AnalysisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-09-26Full publication date if available
- Authors
-
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, Kumi Horii, Kaori Okudera, Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Junko S. Takeuchi, Yunfei Li, Maki Konishi, K. Tsuchiya, Hiroyuki Gatanaga, Shinichi Oka, Tetsuya Mizoue, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Hiroaki Mitsuya, Wataru Sugiura, Norio OhmagariList of authors in order
- Landing page
-
https://doi.org/10.1093/infdis/jiad317Publisher landing page
- PDF URL
-
https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdfDirect OA link when available
- Concepts
-
Neutralizing antibody, Titer, Immunogenicity, Virology, Antibody, Antibody titer, Coronavirus disease 2019 (COVID-19), Medicine, Biology, Immunology, Internal medicine, Disease, Infectious disease (medical specialty)Top concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 5, 2024: 5Per-year citation counts (last 5 years)
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4387087710 |
|---|---|
| doi | https://doi.org/10.1093/infdis/jiad317 |
| ids.doi | https://doi.org/10.1093/infdis/jiad317 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/37756608 |
| ids.openalex | https://openalex.org/W4387087710 |
| fwci | 2.81674658 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000094024 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Post-Acute COVID-19 Syndrome |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D057134 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Antibodies, Neutralizing |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000093742 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Breakthrough Infections |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D000086663 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | COVID-19 Vaccines |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D057216 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Propensity Score |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000086382 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | COVID-19 |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000086402 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | SARS-CoV-2 |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D000914 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Antibodies, Viral |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D006801 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Humans |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D000094024 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Post-Acute COVID-19 Syndrome |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D057134 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Antibodies, Neutralizing |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000093742 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Breakthrough Infections |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000086663 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | COVID-19 Vaccines |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D057216 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Propensity Score |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000086382 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | COVID-19 |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000086402 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | SARS-CoV-2 |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000914 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Antibodies, Viral |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000094024 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Post-Acute COVID-19 Syndrome |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D057134 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Antibodies, Neutralizing |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000093742 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Breakthrough Infections |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000086663 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | COVID-19 Vaccines |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D057216 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Propensity Score |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D000086382 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | COVID-19 |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D000086402 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | SARS-CoV-2 |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000914 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Antibodies, Viral |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D006801 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Humans |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000094024 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Post-Acute COVID-19 Syndrome |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D057134 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Antibodies, Neutralizing |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000093742 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Breakthrough Infections |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D000086663 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | COVID-19 Vaccines |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D057216 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Propensity Score |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D000086382 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | COVID-19 |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D000086402 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | SARS-CoV-2 |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D000914 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Antibodies, Viral |
| type | article |
| title | Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis |
| biblio.issue | 12 |
| biblio.volume | 228 |
| biblio.last_page | 1661 |
| biblio.first_page | 1652 |
| grants[0].funder | https://openalex.org/F4320307779 |
| grants[0].award_id | |
| grants[0].funder_display_name | Roche |
| grants[1].funder | https://openalex.org/F4320310945 |
| grants[1].award_id | |
| grants[1].funder_display_name | Abbott Japan |
| grants[2].funder | https://openalex.org/F4320313449 |
| grants[2].award_id | 19K059 |
| grants[2].funder_display_name | National Center for Global Health and Medicine |
| grants[3].funder | https://openalex.org/F4320313449 |
| grants[3].award_id | 21A2013D |
| grants[3].funder_display_name | National Center for Global Health and Medicine |
| grants[4].funder | https://openalex.org/F4320319612 |
| grants[4].award_id | 2020-B-09 |
| grants[4].funder_display_name | Japan Health Research Promotion Bureau |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T11368 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9998999834060669 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2728 |
| topics[1].subfield.display_name | Neurology |
| topics[1].display_name | Long-Term Effects of COVID-19 |
| topics[2].id | https://openalex.org/T10041 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9997000098228455 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | COVID-19 Clinical Research Studies |
| funders[0].id | https://openalex.org/F4320307779 |
| funders[0].ror | https://ror.org/00by1q217 |
| funders[0].display_name | Roche |
| funders[1].id | https://openalex.org/F4320310945 |
| funders[1].ror | https://ror.org/04v748538 |
| funders[1].display_name | Abbott Japan |
| funders[2].id | https://openalex.org/F4320313449 |
| funders[2].ror | https://ror.org/00r9w3j27 |
| funders[2].display_name | National Center for Global Health and Medicine |
| funders[3].id | https://openalex.org/F4320319612 |
| funders[3].ror | |
| funders[3].display_name | Japan Health Research Promotion Bureau |
| is_xpac | False |
| apc_list.value | 4320 |
| apc_list.currency | USD |
| apc_list.value_usd | 4320 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779261636 |
| concepts[0].level | 3 |
| concepts[0].score | 0.769801139831543 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7003054 |
| concepts[0].display_name | Neutralizing antibody |
| concepts[1].id | https://openalex.org/C32611913 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7586087584495544 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[1].display_name | Titer |
| concepts[2].id | https://openalex.org/C2780868878 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6656548976898193 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1660197 |
| concepts[2].display_name | Immunogenicity |
| concepts[3].id | https://openalex.org/C159047783 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6526276469230652 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[3].display_name | Virology |
| concepts[4].id | https://openalex.org/C159654299 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6414153575897217 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[4].display_name | Antibody |
| concepts[5].id | https://openalex.org/C22889606 |
| concepts[5].level | 4 |
| concepts[5].score | 0.5090476870536804 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[5].display_name | Antibody titer |
| concepts[6].id | https://openalex.org/C3008058167 |
| concepts[6].level | 4 |
| concepts[6].score | 0.4656344950199127 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[6].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.3992881774902344 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C86803240 |
| concepts[8].level | 0 |
| concepts[8].score | 0.39070260524749756 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[8].display_name | Biology |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3214847445487976 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.11336317658424377 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C2779134260 |
| concepts[11].level | 2 |
| concepts[11].score | 0.08740654587745667 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[11].display_name | Disease |
| concepts[12].id | https://openalex.org/C524204448 |
| concepts[12].level | 3 |
| concepts[12].score | 0.05847284197807312 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[12].display_name | Infectious disease (medical specialty) |
| keywords[0].id | https://openalex.org/keywords/neutralizing-antibody |
| keywords[0].score | 0.769801139831543 |
| keywords[0].display_name | Neutralizing antibody |
| keywords[1].id | https://openalex.org/keywords/titer |
| keywords[1].score | 0.7586087584495544 |
| keywords[1].display_name | Titer |
| keywords[2].id | https://openalex.org/keywords/immunogenicity |
| keywords[2].score | 0.6656548976898193 |
| keywords[2].display_name | Immunogenicity |
| keywords[3].id | https://openalex.org/keywords/virology |
| keywords[3].score | 0.6526276469230652 |
| keywords[3].display_name | Virology |
| keywords[4].id | https://openalex.org/keywords/antibody |
| keywords[4].score | 0.6414153575897217 |
| keywords[4].display_name | Antibody |
| keywords[5].id | https://openalex.org/keywords/antibody-titer |
| keywords[5].score | 0.5090476870536804 |
| keywords[5].display_name | Antibody titer |
| keywords[6].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[6].score | 0.4656344950199127 |
| keywords[6].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.3992881774902344 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/biology |
| keywords[8].score | 0.39070260524749756 |
| keywords[8].display_name | Biology |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.3214847445487976 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.11336317658424377 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/disease |
| keywords[11].score | 0.08740654587745667 |
| keywords[11].display_name | Disease |
| keywords[12].id | https://openalex.org/keywords/infectious-disease |
| keywords[12].score | 0.05847284197807312 |
| keywords[12].display_name | Infectious disease (medical specialty) |
| language | en |
| locations[0].id | doi:10.1093/infdis/jiad317 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S54542293 |
| locations[0].source.issn | 0022-1899, 1537-6613 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0022-1899 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | The Journal of Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The Journal of Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/infdis/jiad317 |
| locations[1].id | pmid:37756608 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The Journal of infectious diseases |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/37756608 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5001197457 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6503-8577 |
| authorships[0].author.display_name | Shohei Yamamoto |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[0].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shohei Yamamoto |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[1].author.id | https://openalex.org/A5084560457 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-4757-7128 |
| authorships[1].author.display_name | Kouki Matsuda |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210094533 |
| authorships[1].affiliations[0].raw_affiliation_string | Japan Foundation for AIDS Prevention , Tokyo , Japan |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210094012 |
| authorships[1].affiliations[1].raw_affiliation_string | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I107139324 |
| authorships[1].affiliations[2].raw_affiliation_string | Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University , Kagoshima , Japan |
| authorships[1].institutions[0].id | https://openalex.org/I107139324 |
| authorships[1].institutions[0].ror | https://ror.org/03ss88z23 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I107139324 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Kagoshima University |
| authorships[1].institutions[1].id | https://openalex.org/I4210094012 |
| authorships[1].institutions[1].ror | https://ror.org/00r9w3j27 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210094012 |
| authorships[1].institutions[1].country_code | JP |
| authorships[1].institutions[1].display_name | National Center for Global Health and Medicine |
| authorships[1].institutions[2].id | https://openalex.org/I4210094533 |
| authorships[1].institutions[2].ror | https://ror.org/007wxbw11 |
| authorships[1].institutions[2].type | facility |
| authorships[1].institutions[2].lineage | https://openalex.org/I4210094533 |
| authorships[1].institutions[2].country_code | JP |
| authorships[1].institutions[2].display_name | The Dia Foundation for Research on Ageing Societies |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kouki Matsuda |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan, Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University , Kagoshima , Japan, Japan Foundation for AIDS Prevention , Tokyo , Japan |
| authorships[2].author.id | https://openalex.org/A5055989025 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9424-1491 |
| authorships[2].author.display_name | Kenji Maeda |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I107139324 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University , Kagoshima , Japan |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I4210094012 |
| authorships[2].affiliations[1].raw_affiliation_string | Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[2].institutions[0].id | https://openalex.org/I107139324 |
| authorships[2].institutions[0].ror | https://ror.org/03ss88z23 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I107139324 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Kagoshima University |
| authorships[2].institutions[1].id | https://openalex.org/I4210094012 |
| authorships[2].institutions[1].ror | https://ror.org/00r9w3j27 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210094012 |
| authorships[2].institutions[1].country_code | JP |
| authorships[2].institutions[1].display_name | National Center for Global Health and Medicine |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kenji Maeda |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine , Tokyo , Japan, Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University , Kagoshima , Japan |
| authorships[3].author.id | https://openalex.org/A5108332696 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Kumi Horii |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[3].affiliations[0].raw_affiliation_string | Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[3].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Kumi Horii |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[4].author.id | https://openalex.org/A5059325051 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Kaori Okudera |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[4].affiliations[0].raw_affiliation_string | Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine , Chiba , Japan |
| authorships[4].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[4].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Kaori Okudera |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine , Chiba , Japan |
| authorships[5].author.id | https://openalex.org/A5045100927 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Yusuke Oshiro |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[5].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Yusuke Oshiro |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[6].author.id | https://openalex.org/A5051755149 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Natsumi Inamura |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[6].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[6].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Natsumi Inamura |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[7].author.id | https://openalex.org/A5044167258 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Takashi Nemoto |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[7].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[7].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Takashi Nemoto |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[8].author.id | https://openalex.org/A5006409532 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4844-9013 |
| authorships[8].author.display_name | Junko S. Takeuchi |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[8].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Junko S Takeuchi |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[9].author.id | https://openalex.org/A5100461864 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8413-0026 |
| authorships[9].author.display_name | Yunfei Li |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[9].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[9].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Yunfei Li |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[10].author.id | https://openalex.org/A5058847401 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Maki Konishi |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[10].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[10].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Maki Konishi |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[11].author.id | https://openalex.org/A5037218495 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-8233-6653 |
| authorships[11].author.display_name | K. Tsuchiya |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[11].affiliations[0].raw_affiliation_string | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[11].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[11].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Kiyoto Tsuchiya |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[12].author.id | https://openalex.org/A5029414324 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-9191-9984 |
| authorships[12].author.display_name | Hiroyuki Gatanaga |
| authorships[12].countries | JP |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[12].affiliations[0].raw_affiliation_string | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[12].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[12].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[12].institutions[0].country_code | JP |
| authorships[12].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Hiroyuki Gatanaga |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[13].author.id | https://openalex.org/A5072097342 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-9283-2167 |
| authorships[13].author.display_name | Shinichi Oka |
| authorships[13].countries | JP |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[13].affiliations[0].raw_affiliation_string | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[13].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[13].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[13].institutions[0].country_code | JP |
| authorships[13].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Shinichi Oka |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[14].author.id | https://openalex.org/A5014601065 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-1198-2228 |
| authorships[14].author.display_name | Tetsuya Mizoue |
| authorships[14].countries | JP |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[14].affiliations[0].raw_affiliation_string | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[14].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[14].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[14].institutions[0].country_code | JP |
| authorships[14].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Tetsuya Mizoue |
| authorships[14].is_corresponding | True |
| authorships[14].raw_affiliation_strings | Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[15].author.id | https://openalex.org/A5072936823 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-7849-1327 |
| authorships[15].author.display_name | Haruhito Sugiyama |
| authorships[15].countries | JP |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[15].affiliations[0].raw_affiliation_string | Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[15].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[15].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[15].institutions[0].country_code | JP |
| authorships[15].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Haruhito Sugiyama |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Center Hospital of the National Center for the Global Health and Medicine , Tokyo , Japan |
| authorships[16].author.id | https://openalex.org/A5023373849 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-8037-6440 |
| authorships[16].author.display_name | Nobuyoshi Aoyanagi |
| authorships[16].countries | JP |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[16].affiliations[0].raw_affiliation_string | Kohnodai Hospital of the National Center for the Global Health and Medicine , Chiba , Japan |
| authorships[16].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[16].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[16].institutions[0].country_code | JP |
| authorships[16].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Nobuyoshi Aoyanagi |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Kohnodai Hospital of the National Center for the Global Health and Medicine , Chiba , Japan |
| authorships[17].author.id | https://openalex.org/A5034448543 |
| authorships[17].author.orcid | https://orcid.org/0000-0001-9274-3853 |
| authorships[17].author.display_name | Hiroaki Mitsuya |
| authorships[17].countries | JP |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[17].affiliations[0].raw_affiliation_string | Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[17].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[17].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[17].institutions[0].country_code | JP |
| authorships[17].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Hiroaki Mitsuya |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[18].author.id | https://openalex.org/A5032031868 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-3132-0918 |
| authorships[18].author.display_name | Wataru Sugiura |
| authorships[18].countries | JP |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[18].affiliations[0].raw_affiliation_string | Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[18].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[18].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[18].institutions[0].country_code | JP |
| authorships[18].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Wataru Sugiura |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[19].author.id | https://openalex.org/A5067354013 |
| authorships[19].author.orcid | https://orcid.org/0000-0002-4622-8970 |
| authorships[19].author.display_name | Norio Ohmagari |
| authorships[19].countries | JP |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[19].affiliations[0].raw_affiliation_string | Disease Control and Prevention Center, National Center for Global Health and Medicine , Tokyo , Japan |
| authorships[19].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[19].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[19].institutions[0].country_code | JP |
| authorships[19].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[19].author_position | last |
| authorships[19].raw_author_name | Norio Ohmagari |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Disease Control and Prevention Center, National Center for Global Health and Medicine , Tokyo , Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W2363693236, https://openalex.org/W4385850546, https://openalex.org/W4321792944, https://openalex.org/W391733525, https://openalex.org/W1678510290, https://openalex.org/W1991270129, https://openalex.org/W2374971639, https://openalex.org/W3176239880, https://openalex.org/W2052465442, https://openalex.org/W3185521317 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 5 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/infdis/jiad317 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S54542293 |
| best_oa_location.source.issn | 0022-1899, 1537-6613 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0022-1899 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | The Journal of Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The Journal of Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/infdis/jiad317 |
| primary_location.id | doi:10.1093/infdis/jiad317 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S54542293 |
| primary_location.source.issn | 0022-1899, 1537-6613 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0022-1899 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | The Journal of Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad317/51730371/jiad317.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The Journal of Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/infdis/jiad317 |
| publication_date | 2023-09-26 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W4281291961, https://openalex.org/W4226287603, https://openalex.org/W4200579619, https://openalex.org/W4317696178, https://openalex.org/W4283319609, https://openalex.org/W4283171904, https://openalex.org/W4315779712, https://openalex.org/W3162528078, https://openalex.org/W4293214352, https://openalex.org/W2086493164, https://openalex.org/W4317743572, https://openalex.org/W4297152427, https://openalex.org/W4378071832, https://openalex.org/W4295898295, https://openalex.org/W4302009688, https://openalex.org/W4296784260, https://openalex.org/W4323808759, https://openalex.org/W4321369243, https://openalex.org/W4221131277, https://openalex.org/W4316014106, https://openalex.org/W6839657452, https://openalex.org/W3212447088, https://openalex.org/W3136955306, https://openalex.org/W4286269470 |
| referenced_works_count | 24 |
| abstract_inverted_index.2 | 193 |
| abstract_inverted_index.6 | 49 |
| abstract_inverted_index.a | 53, 197 |
| abstract_inverted_index.(1 | 42 |
| abstract_inverted_index.We | 24, 60 |
| abstract_inverted_index.at | 78 |
| abstract_inverted_index.in | 33, 39, 113, 139, 199 |
| abstract_inverted_index.of | 8, 56, 101, 181 |
| abstract_inverted_index.on | 5 |
| abstract_inverted_index.vs | 157 |
| abstract_inverted_index.we | 92 |
| abstract_inverted_index.64% | 126 |
| abstract_inverted_index.72% | 133 |
| abstract_inverted_index.CI, | 135 |
| abstract_inverted_index.and | 17, 69, 72, 80, 85, 99, 107, 122, 132, 159 |
| abstract_inverted_index.are | 3 |
| abstract_inverted_index.but | 206 |
| abstract_inverted_index.may | 195 |
| abstract_inverted_index.not | 177, 207 |
| abstract_inverted_index.the | 6, 89, 202 |
| abstract_inverted_index.who | 35 |
| abstract_inverted_index.(95% | 127, 134 |
| abstract_inverted_index.2022 | 41 |
| abstract_inverted_index.BA.5 | 15, 46, 124, 162, 204 |
| abstract_inverted_index.Data | 2 |
| abstract_inverted_index.June | 40 |
| abstract_inverted_index.dose | 55 |
| abstract_inverted_index.live | 62 |
| abstract_inverted_index.long | 18, 102, 182, 209 |
| abstract_inverted_index.mRNA | 58 |
| abstract_inverted_index.more | 150 |
| abstract_inverted_index.play | 196 |
| abstract_inverted_index.role | 7, 198 |
| abstract_inverted_index.than | 115, 141, 154, 168 |
| abstract_inverted_index.them | 82 |
| abstract_inverted_index.type | 68, 121 |
| abstract_inverted_index.were | 111, 125, 149, 165, 176 |
| abstract_inverted_index.wild | 67, 120 |
| abstract_inverted_index.with | 144, 179 |
| abstract_inverted_index.(RBD) | 75 |
| abstract_inverted_index.Among | 88, 171 |
| abstract_inverted_index.BA.5, | 71 |
| abstract_inverted_index.Tokyo | 34 |
| abstract_inverted_index.[CI], | 130 |
| abstract_inverted_index.acute | 189 |
| abstract_inverted_index.after | 51 |
| abstract_inverted_index.among | 29, 152 |
| abstract_inverted_index.blood | 37 |
| abstract_inverted_index.cases | 84, 114, 140, 155 |
| abstract_inverted_index.lower | 112 |
| abstract_inverted_index.month | 43 |
| abstract_inverted_index.staff | 32 |
| abstract_inverted_index.their | 160 |
| abstract_inverted_index.third | 54 |
| abstract_inverted_index.(10.3% | 156 |
| abstract_inverted_index.0.8%), | 158 |
| abstract_inverted_index.COVID. | 103, 183, 210 |
| abstract_inverted_index.before | 44 |
| abstract_inverted_index.cases, | 91, 172 |
| abstract_inverted_index.domain | 74 |
| abstract_inverted_index.higher | 167 |
| abstract_inverted_index.lower, | 137 |
| abstract_inverted_index.months | 50 |
| abstract_inverted_index.nested | 26 |
| abstract_inverted_index.severe | 188 |
| abstract_inverted_index.titers | 65, 77, 98, 110, 118, 164, 175 |
| abstract_inverted_index.wave), | 47 |
| abstract_inverted_index.(COVID) | 21 |
| abstract_inverted_index.Methods | 23 |
| abstract_inverted_index.Omicron | 14, 45, 70, 123, 146, 161, 203 |
| abstract_inverted_index.Results | 104 |
| abstract_inverted_index.against | 13, 66, 119, 187, 201 |
| abstract_inverted_index.between | 83, 95 |
| abstract_inverted_index.disease | 20 |
| abstract_inverted_index.donated | 36 |
| abstract_inverted_index.humoral | 10 |
| abstract_inverted_index.limited | 4 |
| abstract_inverted_index.samples | 38 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.COVID-19 | 57 |
| abstract_inverted_index.analysis | 28 |
| abstract_inverted_index.anti-RBD | 106 |
| abstract_inverted_index.antibody | 64, 76, 97, 109, 174 |
| abstract_inverted_index.compared | 81 |
| abstract_inverted_index.controls | 153 |
| abstract_inverted_index.examined | 93 |
| abstract_inverted_index.frequent | 151 |
| abstract_inverted_index.hospital | 31 |
| abstract_inverted_index.immunity | 11 |
| abstract_inverted_index.interval | 129 |
| abstract_inverted_index.measured | 61 |
| abstract_inverted_index.previous | 145 |
| abstract_inverted_index.syndrome | 191 |
| abstract_inverted_index.tertiary | 30 |
| abstract_inverted_index.vaccine. | 59 |
| abstract_inverted_index.12.8-fold | 166 |
| abstract_inverted_index.BA.1/BA.2 | 147 |
| abstract_inverted_index.conducted | 25 |
| abstract_inverted_index.controls. | 87, 116, 142 |
| abstract_inverted_index.incidence | 100, 180 |
| abstract_inverted_index.infection | 16, 205 |
| abstract_inverted_index.receiving | 52 |
| abstract_inverted_index.42%–77%) | 131 |
| abstract_inverted_index.53%–83%) | 136 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.associated | 178 |
| abstract_inverted_index.confidence | 128 |
| abstract_inverted_index.infections | 148 |
| abstract_inverted_index.preventing | 208 |
| abstract_inverted_index.protecting | 200 |
| abstract_inverted_index.protection | 12 |
| abstract_inverted_index.Conclusions | 184 |
| abstract_inverted_index.Individuals | 143 |
| abstract_inverted_index.association | 94 |
| abstract_inverted_index.coronavirus | 19, 192 |
| abstract_inverted_index.respiratory | 190 |
| abstract_inverted_index.(SARS-CoV-2) | 194 |
| abstract_inverted_index.Neutralizing | 117 |
| abstract_inverted_index.Preinfection | 105, 185 |
| abstract_inverted_index.breakthrough | 90 |
| abstract_inverted_index.case-control | 27 |
| abstract_inverted_index.development. | 22 |
| abstract_inverted_index.individuals. | 170 |
| abstract_inverted_index.neutralizing | 108, 163 |
| abstract_inverted_index.preinfection | 9, 96, 173 |
| abstract_inverted_index.approximately | 48 |
| abstract_inverted_index.preinfection, | 79 |
| abstract_inverted_index.respectively, | 138 |
| abstract_inverted_index.immunogenicity | 186 |
| abstract_inverted_index.infection-naive | 169 |
| abstract_inverted_index.propensity-matched | 86 |
| abstract_inverted_index.virus-neutralizing | 63 |
| abstract_inverted_index.anti–receptor-binding | 73 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5001197457, https://openalex.org/A5014601065 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 20 |
| corresponding_institution_ids | https://openalex.org/I4210094012 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.88479771 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |